Adanate is exploiting a family of proteins, called leukocyte immunoglobulin-like receptor B (LILRBs), which are involved in preventing an appropriate host response to cancer or infectious disease. In cancer, LILRBs work by dampening the immune response and creating an immunosuppressive environment within solid tumors. Adanate has generated numerous antibody drug candidates that can block the activity and function of LILRBs. The antibodies work by converting a type of white blood cell, macrophages, from one activation state (M2) to another (M1). M1 macrophages have the potential to kill cancer cells. The antibodies can also generate an appropriate T-cell response against the cancer which can also lead to shrinkage of the tumor. The company plans to advance these new drug candidates towards clinical development by the end of 2018.